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SIGNIFICANCE
Intravenous iron solution drugs are increasingly used to 
treat iron deficiency. A rare side-effect is paravenous ex-
travasation of iron preparations, resulting in cutaneous si-
derosis. Pigment-targeting lasers have been used to treat 
these hyperpigmentations with variable success. The opti-
mal treatment protocol remains unclear. This retrospective 
study with 15 patients aimed to assess the response of 
cutaneous iron deposit after treatment with pigment lasers 
and to determine optimal treatment parameters. The effec-
tiveness of laser treatments was evaluated using a 5-point 
grading system. In all 15 patients a clearance of at least 
50% was obtained. In 12 patients, at least 75% of pigment 
was removed.
Intravenous ferric carboxymaltose is increasingly 
used to treat iron deficiency. However, a common si-
de-effect is paravenous extravasation of iron prepara-
tions, resulting in cutaneous siderosis. Quality-switch-
ed (QS) lasers and, recently, picosecond (PS) lasers 
have been used to treat these hyperpigmentations 
with variable success. The optimal treatment protocol 
remains unclear. The aims of this study were to assess 
the response of cutaneous siderosis to treatment with 
pigment lasers and to determine the optimal wavel-
ength, number of treatment sessions and pulse dura-
tion. Fifteen patients with cutaneous siderosis on the 
arms were included. The effectiveness of laser treat-
ment was evaluated using a 5-point standard Physician 
Global Assessment (PGA) grading system. Differences 
in continuous variables between distinct groups of pa-
tients were assessed with a Mann–Whitney U test. In 
all 15 patients clearance of at least 50% was obtained. 
In 12 patients, at least 75% of pigment was removed. 
In conclusion, pigment lasers are an effective and safe 
method to treat cutaneous siderosis. 
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Iron deficiency is the most common nutritional disorder worldwide and the most common cause of anaemia. 
Iron deficiency affects more than 2 billion people world-
wide. In Europe, the prevalence of iron deficiency has 
been estimated at between 12% and 40% (1, 2).
Lack of iron may result in chronic fatigue, depression, 
restless legs syndrome, irritability and hair loss (2–4). 
Parenteral iron replacement has become popular in 
recent decades, particularly in patients with intolerable 
side-effects with oral treatment, non-compliance or unsa-
tisfactory effect of oral supplementation. In Switzerland, 
parenteral iron replacement has been increasingly used 
in primary care centres, and its use is 1,000-fold higher 
than in the UK (1). Ferric carboxymaltose is, by far, the 
most used drug in Switzerland for intravenous iron supp-
lementation. In addition to serious side-effects, including 
fatal allergic reactions (5), another well-recognized 
complication is the development of a greyish-brown 
hyperpigmentation as a result of the paravenous leakage 
of intravenous iron, leading to cutaneous siderosis (6–8). 
Due to this poor aesthetic appearance, there is a strong 
need for efficient treatments. To date, however, there are 
scant data in the literature about the possible and most 
efficient therapeutic options. Treatments with quality-
switched (QS) lasers are reported in a few cases with dif-
ferent wavelengths: 532, 755 and 1,064 nm (6, 7, 9–12). 
QS lasers, developed in the 1980s, are efficient in the 
removal of exogenous and endogenous pigments, such as 
tattoos, as well as epidermal and dermal melanin lesions. 
They were the first lasers to demonstrate usefulness in 
the removal of pigments by selective photothermolysis, 
with good aesthetic outcome (13). The laser light emit-
ted at 10–9 s is absorbed by pigment particles, leading to 
fragmentation of these particles by a photothermal and 
photoacoustic effect. Smaller particles can be then phago-
cyted by macrophages, and transported via the lymphatic 
system into the lymph node (14). Furthermore, there are 
reports describing the successful use of QS lasers in the 
management of cutaneous siderosis in stasis dermatitis 
and after sclerotherapy (6).
Recently, the development of picosecond (PS) lasers 
has provided a new tool for pigment removal. Due to a 
shorter pulse duration (300–750 10–12 s), PS lasers are 
more efficient than QS lasers in removing exogenous 
pigments, by acting with a stronger photoacoustic ef-
fect, leading to a smaller fragmentation of the pigments 
(15). However, there is debate about the superiority of 
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PS lasers, which may act more in a sub nano-spectrum 
domain. In fact, in some reports, the PS lasers did not 
appear to show a significant advantage for the treatment 
of tattoos compared with QS lasers (16). The current 
study aimed to evaluate the efficacy of pigment-lasers 
in treating cutaneous siderosis and to explore the effect 
of other clinical variables on treatment response.
MATERIALS AND METHODS
Study design
A retrospective analysis was conducted of 15 consecutive female 
patients treated with lasers for cutaneous siderosis occurring af-
ter extravasation of iron preparations. The study was performed 
between January 2011 and August 2019. None of the patients 
received any previous treatment. Patients were identified in our 
electronic medical report database by the keywords “iron” and 
“siderosis”. Two identified patients were not included as they were 
in poor general health and did not want to travel. Relevant data 
(demographics, localization, type of laser, wavelength, treatment 
session, time to treatment start, time to last picture, side-effects) 
were collected in a standardized clinical report form. The Ethics 
Committee of the Canton of Bern, Switzerland (project ID 2019-
01632) approved the study.
Treatment protocol
All patients, except one, were treated with QS lasers, including 
QS Nd:YAG laser (Revlite and Medlite C6, Cynosure, Westford, 
MA, USA) at 1,064 nm or frequency doubled (a mechanism 
generating radiation with the double frequency of the initial laser 
wavelength, using a non-linear optical material) at 532 nm (in 
14 cases). One patient was treated with a QS ruby laser, at 694 
nm (Sinon, Alma Lasers, Caesarea, Israel). Eleven patients were 
treated with a wavelength of 1,064 nm, 2 with a combination of 
1,064 nm and 532 nm, one with 532 nm and one with 694 nm. A 
spot size of 4 mm was used with the ruby laser, while spot sizes 
of 4–6 mm were used with the Nd:YAG laser, depending on the 
fluence required. When the fluence needed could not be produced 
by the laser with the 6-mm spot, the spot size was changed to 4 
mm to be able to increase the fluence. All patients were treated 
with a fluence leading to an endpoint of a slight purpura. Because 
of pigment lightening after each session, the fluence was increased 
at each session to reach the endpoint mentioned above (fluence 
range: 1,064 nm/6 mm: 0.9–5.8 J/cm2; 1,064 nm/4 mm: 2.1–7.9 J 
J/cm2; 532 nm/6 mm: 0.5–1.4 J/cm2; 532 nm/4 mm: 1.6–2.2 J/cm2). 
Pulse duration in our device is fixed at 5–20 ns. Treatment was 
performed with 10 Hz frequency. No topical anaesthesia was used. 
Post-treatment care included sunscreen SPF 50+, and after the 
first few sessions, a medium-potency topical steroid (mometason 
fuorate cream) was given. The treatment interval was a minimum 
of 4 weeks. Treatment was stopped when the patient was satisfied 
with the aesthetic result and therefore declined further treatment 
sessions. 
In one patient a split-lesion trial was performed with PS 1,064 
nm and QS 1,064 nm.
Histological examination 
In one case, light microscopy studies of a skin biopsy obtained 
from an untreated cutaneous area of siderosis were performed 
to better assess the pigment distribution and pigment depth. The 
histological findings showed a hemosiderosis with presence of 
macrophages with phagocytosed hemosiderin present up to the 
subcutaneous fat. The deposits were predominantly found 2–3 
mm deep, but could also be observed at the lowest margin of the 
biopsy specimen at a depth of 5 mm (Fig. 1).
Evaluation by Physician Global Assessment grading system
Standardized photographs were taken of patients’ iron siderosis 
before and at the earliest 6 weeks after treatment. Five independent 
board-certified dermatologists evaluated clinical improvement, 
defined as clearance of lesion according to a 5-point standard 
Physician Global Assessment (PGA) grading system. The fol-
lowing scale was used: 1: <25%, 2: 25–49%, 3: 50–74%, 4: 
75–90%, and 5: >90%.
The median PGA among all raters (n = 5) was taken as the main 
study outcome and its distribution was tested against a reference 
score of 2 points in the PGA scale (poor improvement). 
Statistical analysis
Descriptive statistics were reported as absolute and relative 
frequencies for nominal variables, while means with standard 
deviations (SD) and medians with ranges were used for continu-
ous variables. One sample Wilcoxon signed-rank test was used to 
assess overall PGA difference from a reference score of 2. PGA 
differences between distinct groups of patients were assessed by 
using Mann–Whitney U test. For continuous variables, the optimal 
cut-off threshold was computed based on the significance of the test.
Fig. 1. Histopathological findings. (A) Iron deposit (Berlin-blue stain x20) in the whole dermis (predominantly 2–3 mm depth) and subcutis. (B) 
Presence of macrophages with phagocytosed hemosiderin (haematoxylin-eosin stain x200).
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Absolute agreement among assessors for the overall PGA was 
calculated by using intraclass correlation coefficient (ICC) with 
2-way random mean measure and reported with its 95% confidence 
interval (95% CI). All tests were considered statistically significant 
at p-value < 0.05. Analyses were performed with SPSS v.26 (IBM 
Corp. Armonk, NY, USA).
RESULTS
Demographics and treatment location
All 15 patients were female, with a Fitzpatrick’s skin 
photo-type I–IV. The median age at first treatment was 
43 years (range 15–66 years). Cutaneous siderosis was 
found on the elbow pit in 12 (80%) of 15 patients and 
on the wrist in the remaining 3 patients (20%). A total 
of 2–9 treatment sessions were performed (mean ± SD: 
4.5 ± 2.4). The mean ± SD treatment interval was 2.4 ± 1.0 
months (range 4–45 weeks). The mean ± SD time from 
iron perfusion to initiation of laser treatment was 9.6 ± 5.3 
months (Table I).
Correlation between overall PGA and follow-up time 
was not significant (p = 0.29).
Clearance according to Physician Global Assessment
The overall median PGA of 4 (range 3–4) was signifi-
cantly higher than a reference value of 2 (poor impro-
vement). Five of the patients (33.3%) had an overall 
clearance rate of 5, corresponding to a response of over 
90%. Hence, all patients achieved a clearance of at least 
50%. The ICC among assessors for the overall PGA is 
0.76 (95% CI: 0.50–0.91), corresponding to a substantial 
agreement (Table II).
Anatomical location
It was observed that more laser sessions (7.3 ± 2.9) were 
needed to achieve patient satisfaction when treating 
cutaneous siderosis on the wrists compared with other 
anatomical locations (3.8 ± 1.7) (p = 0.048). No signifi-
cant difference was observed between other anatomical 
locations. In general, a better clearance rate was obser-
ved when the treatment was performed over 4 or more 
sessions (p = 0.03).
Wavelength
There were apparently no significant differences in terms 
of efficacy between 1,064 nm and 532 nm (single or in 
combination with 1,064 nm). The number of treatment 
sessions was independent of the wavelength used.
Pulse duration
In one patient, a split treatment with QS laser and PS 
laser was performed during the first session. A slightly 
better clearance was observed with QS lasers.
Side-effects
During laser treatment, all patients felt a burning 
sensation, but no anaesthetic ointment was needed or 
requested by the patients. The slight purpura obtained 
as the endpoint of the treatment invariably resolved 
within 10 days in all patients. In one case (Fitzpatrick’s 
skin photo-type III), temporary hyperpigmentation and 
prolonged erythema were observed after treatment with 
QS and PS at 532 nm. These side-effects disappeared 
spontaneously within 4 months. No other persistent 
side-effect was observed. 
Table I. Survey of the clinical characteristics and treatment protocol 
of the 15 patients 
n (%) Mean (SD) Median (range)
Age at start, years 43.3 (11.3) 43 (15–66)
Localization*
  Elbow 12 (80.0)
  Wrist 3 (20.0)
  Forearm 1 (6.7)
Sessions 4.5 (2.4) 4 (2–9)
Wavelength, nm*
  1,064 14 (93.3)
  532 3 (20.0)
  694 1 (6.7)
Treatment duration, months 11.6 (8.3) 8.0 (2.0–31.0)
Interval between sessions, months 2.4 (1.0) 2.0 (1.0–4.8)
Time to start, months 9.6 (5.3) 8.0 (4.0–24.0)
Time of follow-up, months 23.7 (30.8) 6.0 (2.0–96.
Overall PGA scale** 4.2 (0.7) 4 (3–5)
  3: 50–74 % 2 (13.3)
  4: 75–90 % 8 (53.3)
  5: >90 % 5 (33.3)
*Multiple categories are possible. **Median among all raters (n = 5).
PGA: physician global assessment; SD: standard deviation.
Table II. Overall efficacy according to localization, number of 
sessions and wavelength of laser
Overall PGA scale
p-value*n (%) Mean (SD) Median (range)
Localization
Elbow
  No   3 (20) 4.7 (0.6) 5 (4–5) 0.23
  Yes 12 (80) 4.1 (0.7) 4 (3–5)
Wrist
  No 12 (80) 4.1 (0.7) 4 (3–5) 0.23
  Yes   3 (20) 4.7 (0.6) 5 (4–5)
Forearm
  No 14 (93.3) 4.1 (0.7) 4 (3–5) 0.40
  Yes   1 (6.7) 5.0 (nc) 5 (nc)
Sessions
  < 4 6 (40) 3.7 (0.5) 4 (3–4) 0.03
  ≥ 4 9 (60) 4.6 (0.5) 5 (4–5)
Wavelength
1,064 nm
  No 1 (6.7) 5.0 (nc) 5 (nc) 0.40
  Yes 14 (93.3) 4.1 (0.7) 4 (3–5)
532 nm
  No 12 (80) 4.3 (0.6) 4 (3–5) 0.73
  Yes   3 (20) 4.0 (1.0) 4 (3–5)
694 nm
  No 14 (93.3) 4.2 (0.7) 4 (3–5) 0.80
  Yes   1 (6.7) 4.0 (nc) 4 (nc)
*Mann–Whitney U test.
nc: not computable; PGA: Physician Global Assessment; SD: standard deviation.
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DISCUSSION
Paravenous leakage of intravenous iron at the infusion 
site results in circumscribed greyish to brown hyper-
pigmentation in 1.6–1.8% of treated patients (8). Skin 
hyperpigmentation is persistent and does not resolve 
spontaneously, causing significant psychological stress 
for patients. Using light microscopy studies, the exoge-
nous pigment is found within numerous macrophages 
in all dermal layers as well as in the subcutaneous fat 
tissue. Therefore, superficial treatments, such as creams, 
peelings and dermabrasion, are not effective (12).
Only a few case reports and one case series, focusing 
on the effectiveness of removal of cutaneous siderosis, 
have been published in English (6, 7, 9–12). The current 
retrospective study of 15 treated patients represents the 
largest series reported so far. The findings show that QS 
lasers are efficient and useful in the management of cuta-
neous siderosis due to paravenous leakage of intravenous 
iron (Fig. 2). With a mean of 4.5 treatment sessions, a 
clearance of at least 50% was observed in all patients.
For most patients a QS YAG laser at 1,064 nm was 
used to remove the pigment. A few lesions were also 
treated with other wavelengths (either 532 nm or 694 
nm) or with shorter pulse durations (350–550 ps). As 
we performed these comparisons only within the first 
session, it is difficult to draw any conclusion as to which 
wavelength or which pulse duration is superior. This can 
be explained both by the limited study sample size and 
power for this kind of analysis. Furthermore, the dif-
ferent wavelengths have advantages and disadvantages 
concerning their penetration depth and absorption peak. 
Iron has a major absorption peak at 410–415 nm (6). 
Ferric carboxymaltose has no distinct maximum absorp-
tion wavelength. However, there is an absorption band 
at around 470–500 nm (17, 18), explaining the good 
response to 532 nm lasers. Nevertheless, it is likely that 
the comparable overall rating of the 532 nm and 1,064 
nm wavelength is that the penetration depth of the 532 
nm wavelength is not deep enough. Furthermore, the risk 
of post-inflammatory hyperpigmentation is higher with 
the 532 nm than the 1,064 nm wavelengths, especially 
in darker skin types. The latter may thus pose a dilemma 
for both the treatment and evaluation by the physician. In 
one patient, combined treatment was given: QS 532 nm 
followed by QS 1,064 nm. However, the results obtained 
in this case do not support the idea that the combination 
is superior to the use of a single wavelength. Our overall 
findings indicate that more than 4 treatment sessions 
resulted in a better response rate. In analogy with what 
has been observed and reported for tattoos on the extre-
mities, such as wrist and ankle, successful treatment of 
cutaneous siderosis involving the wrist required more 
treatment sessions.
Besides the wavelength, spot size also influences the 
penetration depth of the laser. Light scatters at the border 
Fig. 2. Treatment of cutaneous siderosis with quality-switched (QS) lasers. Lesion in the elbow (a) before and (b) after 5 treatment sessions 
with QS 1,064 nm laser. Cutaneous siderosis on the wrist (c) before and (d) after 9 sessions with QS 1,064 nm laser. Lesion on the elbow and forearm 
(e) before and (f) after 6 laser sessions with QS 1,064 laser.
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of the target zone (19). Therefore, a smaller spot size will 
result in a greater proportion of the light being scattered, 
leading to less depth in penetration of light. 
As the pigment in cutaneous siderosis is lying deep, the 
largest possible spot-size with the required fluence should 
be chosen in order to reach the deepest pigment possible.
Side-effects were limited to a mild burning sensation, 
lasting a few hours and a slight purpura, resolving within 
7–10 days. We did not observe any case of hypopigmen-
tation or blistering, as reported in another case series 
(12). These complications are probably best avoided by 
adapting wavelength to the skin type. 
Some papers describe that PS lasers are more efficient 
in tattoo removal than QS lasers (15), excluding some 
above-mentioned exceptions. Considering histological 
similarities between iatrogenic cutaneous siderosis and 
decorative tattoos, it was a reasonable assumption that 
PS lasers would have been more efficient than QS lasers 
in the removal of cutaneous siderosis. Furthermore, 
the median core diameters of the 2 available ferric car-
boxymaltose products in Switzerland are 5.0 ± 0.8 nm 
(Venofer®, Venofer, Vifor (International) Inc., St. Gallen, 
Switzerland) and 11.7 ± 44 nm (Ferinject®, Vifor (Inter-
national) Inc.) (20). These reported sizes are therefore 
even smaller than the mean size of a black ink particle 
(50–400 nm), a further reason that PS lasers should be 
more efficient. Nonetheless, in our split-lesion case, 
there was no obvious difference between the observed 
results. Nevertheless, additional studies that include a 
larger number of cases are required to definitively add-
ress this issue. 
In conclusion, physicians should be familiar with the 
best treatment options of iatrogenic cutaneous siderosis, 
as increasing cases can be expected. Our retrospective 
study indicates that QS lasers are an effective and safe 
method. Different wavelengths appear to be useful for 
treatment, because the penetration depth (which is dee-
per with longer wavelength) is equally important as the 
absorption peak of iron (415 nm). Somehow, surprisingly 
our preliminary findings do not support the ideas that 
PS are more efficient than QS lasers in the removal of 
cutaneous siderosis, although the particle size of iron 
particles is very small. However, randomized controlled 
trials with a higher number of patients are needed to draw 
any definitive conclusion. 
The authors have no conflicts of interest to declare.
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